
    
      -  20 relapsed or refractory advanced mycosis fungoides/Sezary syndrome patients are
           scheduled with gradually escalated doses (3 mg, 10 mg , and 30 mg) on sequential days
           during the first week, followed by 30 mg three times a week until 12 weeks.

        -  Patients must have serology negative for human T-lymphotropic virus 1 (HTLV-1) and until
           three different regimens of chemotherapy.

        -  Follow up for one year after last cycle of alemtuzumab.
    
  